Bio-Rad Laboratories BIO (Payments for) proceeds from forward foreign exchange contracts, net
(Payments for) proceeds from forward foreign exchange contracts, net at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept bio:Proceedsfromderivativeinstrumentsoperatingactivities.
The official record: Bio-Rad Laboratories’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net?
- Bio-Rad Laboratories (BIO) reported (payments for) proceeds from forward foreign exchange contracts, net of -$9.53M in Q4 2025.
- How has Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net changed year-over-year?
- Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net decreased by 289.6% year-over-year, from $5.03M to -$9.53M.
- What is the long-term trend for Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's (payments for) proceeds from forward foreign exchange contracts, net has grown at a 32.0% compound annual growth rate (CAGR), from $12.57M to -$38.1M.
- What does (payments for) proceeds from forward foreign exchange contracts, net mean?
- Represents the net cash impact of derivative financial instruments used for hedging operational risks, such as foreign exchange or commodity price fluctuations. This metric reflects the cash-flow impact of the company's risk management activities.